Sirs,
The benefits of statins in reducing the risk of cardiovascular (CV) events in various high-risk patient groups are wellestablished [1, 2] . It has recently been suggested that CV event rates can be reduced even further by using more intensive versus less intensive statin therapy [3] . Despite the widespread and increasing use of statins [4, 5] , the benefits may be diluted due to the prescription of doses lower than those shown to be effective in randomized trials [6] [7] [8] .
Finland, as many other countries, has implemented policies to contain statin costs [9] . Beginning in October 2006, reimbursement of the most expensive statins, atorvastatin and rosuvastatin, was restricted to the treatment of severe lipid metabolism disorders in high-risk patients when less expensive statins were ineffective or not tolerated. We sought to characterize new statin users in the fall 2007, approximately 1 year after this restriction was implemented in terms of the type and dose of the initial statin and CV risk status. The new statin users were also followed up for 1 year postdrug initiation to detect potential changes in the therapy.
Using the Prescription Register maintained by the Social Insurance Institution of Finland (SII) [10] , we identified a cohort of individuals aged ≥18 years who purchased statins for the first time between 1 September and 31 December 2007 (referred to as "initiators"). Initiators had not purchased statins during the 3 years preceding entry into the study. Individuals who were institutionalized permanently or died within 1 year following initiation and those using lipid-modifying drugs (World Health Organization Anatomical Therapeutic Chemical classification code C10) other than statins (C10AA) at cohort entry were excluded. The CV risk status of the initiators was classified as high, moderate, or low based on diagnostic information extracted from the SII Special Reimbursement Register and purchases of CV drugs during the preceding year (Table 1) .
Statin therapy was typically initiated with simvastatin (94% of the cohort) as 10-or 20-mg tablets (Table 1) . Only every fifth simvastatin initiator received 40-mg tablets, and 0.1% of simvastatin initiators received 80-mg tablets. Atorvastatin use was most commonly initiated with 10-or 20-mg tablets. Almost one third of the cohort was classified as having a high CV risk. Of those with a high CV risk, 20% initiated statin use with 10-mg simvastatin tablets and 48% with 20-mg simvastatin tablets; an additional 3% initiated statin therapy with other low-potent statin doses [11] . Of all the simvastatin initiators, 20% switched to another dose or to another lipid-lowering medication within 1 year of initiating statin therapy, with 4% switching to atorvastatin or rosuvastatin. Among those who initiated statin therapy with rosuvastatin, atorvastatin, pravastatin, and fluvastatin, the proportions of those switching dose or medication were 21, 29, 31, and 34%, respectively. Between 9 and 14% of the initiators purchased only one prescription during the first year.
In compliance with the reimbursement restriction [9] , a vast majority of new statin users in the fall 2007 in Finland were prescribed simvastatin. However, potential underdosing at initiation was common, even among patients with a high CV risk. A considerable proportion of those initiating statin therapy with less potent doses also remained at the initial dose after 1 year. Furthermore, the wholesale statistics show that, of all statin tablets sold in Finland in 2010, 21% were 10-mg simvastatin tablets and 49% were 20-mg simvastatin tablets [12] . That is, most simvastatin users in Finland still received doses lower than the 40-mg dose used in many clinical trials [2, 13] and recommended by current clinical guidelines [14, 15] . While this study has limitations due to the reliance on the SII data on drug use and comorbidities, the results support the notion that potential benefits of statin therapy may be compromised due to low doses prescribed at the initiation of this therapy and during the following year.
